Third Rock Thinks Its Model Reassures Investors In Difficult Times

Venture Firm Raised $1.1bn Fund VI, Its Largest Yet

New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.

Venture Capital Concept on the Mechanism of Metal Gears.
Third Rock Ventures raises $1.1bn sixth fund • Source: Shutterstock

Market turmoil and declining valuations in biotech are not deterring Third Rock Ventures from doing what it has done since 2007: raising funds of increasing size to back new biotechs that it incubates internally. Partner Abbie Celniker explained to Scrip that the venture capital firm’s long-term planning, and having long-term investors, makes it less susceptible to market conditions.

On 15 June, the Boston-based venture capital firm announced it has raised $1.1bn, its biggest fund to date and one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.